NCT07623655Not yet recruiting
CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia
Observational Retrospective and Prospective Multicentric Study on CAR-T Cell for the Treatment of Pediatric and Adult B-cell Acute Lymphoblastic Leukemia
Source: ClinicalTrials.gov · Last updated 3 Jun 2026
Brief summary (registry, in English)
The goal of this observational study is to evaluate the efficacy of the treatment with approved CAR-T cells in Italy in pediatric and adult patients with acute B-cell lymphoblastic leukemia. The main question it aims to answer is: which is the overall response rate in pediatric and adult patients with acute B-cell lymphoblastic leukemia treated with approved CAR-T cells? Data will be extracted from patients medical records.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 107 (estimated)
- First submitted
- 29 May 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2029
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- NCT number
- NCT07623655
What you commit to
- Study type: Observational
- Planned participants: 107
- From 1 Sept 2026 to the primary completion date, 1 Sept 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
- \-
Who the study is looking for
- Diagnosis of ALL R/R CD19+
- Patients are pediatric (all patients up to the age of 18) adult (all comers older than 18)
- Prescribed treatment with Tisagenlecleucel or Brexucabtagene autoleucel as per approved AIFA criteria, or obecabtagene autoleucel - as well as other products - when available
- Provided consent (or did not opposed) for collection and use of patient data per local regulations
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.